DOCSLIB.ORG

Luna Investments

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Luna Investments Luna Investments - API List Product Name Abacavir Alpha Chymotrypsin Ampicillin + Sulbactum Sterile Abamectin Alpha Lipoic Acid Analgin Abiraterone Alpha Tocopherol Anastrazole Acamprosate Calcium Alprazolam Anidulafungin Acarbose Alprostadil Apixaban Acebrophylline Alprostadil Alfadex Apremislast Acebutolol HCl Althiazide Aprepitant Aceclidine HCl Aluminium Hydroxide Argatroban Acefylline Aluminium Magnesium Hydroxide Aripiprazole Acefylline Piperazine Aluminium Magnesium Silicate Armodafinil Acemetacin Aluminium Monostearate Artemether Acenocoumarol Aluminium Phosphate Artesunate Acetazolamide Aluminum Hydroxide Ascorbic Acid Acetic Anhydride Alverine Citrate Ascorbyl Palmitate Acetonitrile Amantadine hcl Asenapine Maleate Acetyl carnitine hcl Ambriesentan Aspirin Acetyl Chloride Ambroxol Hydrochloride Atazanavir Sulfate Acetyl ethylene urea Ambroxol Theophyllinate Atenolol Acetylcysteine Amcinonide Atomoxetine HCl Acipimox Amfepramone Atorvastatin Acitretin Amifampridine Phosphate Atosiban Acetate Aclidinium Bromide Amifostine Trihydrate Atovaquone Acyclovir Amikacin Atracurium Besylate Adamantane Amiloride HCl Avanafil Adamantanol Amino Pyridine Azacitidine Adamantylacetamide Aminoheptane Sulfate Azelnidipine Adamantylmethylketone Aminophylline Azilsartan Adamtanone Aminosidine Azithromycin Adapalene Amiodarone Aztreonam Adefovir Dipivoxil Amisulpride Bacitracin Adrenaline Amitriptyline Baclofen Aescin Amlodipine Bazedoxifene Afatinib Ammonium Adipate Beclomethasone Dipropionate Agomelatine Ammonium Benzoate Benazepril HCl Albendazole Ammonium Citrate Dibasic Bendamustine HCl Alclomethasone Dipropionate Ammonium Citrate Tribasic Bendroflumethiazide Aldoxorubicin HCl Ammonium Lactate Benfothiamine Alendronate Sodium Ammonium Propionate Benoxinate HCl Alendronic Acid Ammonium Sulphate Benperidol Alfacalcidol Amodiaquine Benproperine Alfaprostol Amorolfine Benzalkonium Bromide Alfuzosin Hydrochloride Amoxicillin Benzalkonium Chloride Amoxicillin + Potassium Alitretinoin Benzbromarone Clavulanate Allopurinol Amphetamine Benzethonium Chloride Almagate Amphoteracin B Benzhexol HCl Almotriptan Malate Ampicillin Benzonanate Alogliptin Ampicillin + Cloxacillin Benzphetamine HCl API List 1/9 Luna Investments Luna Investments - API List Product Name Betahistine Cabocysteine Calcium Sodium Edetate Betamethasone Cadmium Chloride Calcium Stearate Betaxolol HCl Cadmium Sulfate Calcium Succinate Bethanechol Chloride cafetamet Calcium Sulfate Bezafibrate Caffeine Calcium Undecylenate Bicalutamide Calcifediol Camylofin Bimatoprost Calcipotriene Canagiliflozin Biperidine Calcipotriol Candesartan Bisacodyl Calcitonin Capecitabine Bismuth Citrate Calcitriol Capreomycin Bismuth Subcarbonate Calcium Acetate Carbamazepine Bismuth Subsalicylate Calcium Ascorbate Carbasalate Calcium Bisoprolol Fumarate Calcium Aspartate Carbazitaxel Bivalirudin Calcium Benzoate Carbetapentane Citrate Bleomycin Sulfate Calcium Bisglycinate Carbetocin Blonanserin Calcium Boro Gluconate Carbidopa Boceprevir Calcium Bromo Lactobionate Carbinoxamine Maleate Bohemite Calcium Carbonate Carboplatin Boron Citrate Calcium Chloride Dihydrate Carboprost Boron Gluconate Calcium Citrate Carfilzomib Bortezomib Calcium Copper Edetate Carisoprodol Bosentan Calcium D Pantothenate Carmoterol Boswellia Serrata Extract Calcium Dobesilate carnitine hcl dl Brexpiprazole Calcium D-Saccharate carnitine tartarate Brimonidine Tartrate Calcium Ferrous Citrate Carprofen Bromfenac Calcium Folinate Carteolol HCl Bromhexine HCl Calcium Fumarate Carvedilol Bromocriptine Mesylate Calcium Glubionate Caspofungicin Acetate Bromopride Calcium Glucoheptonate Caspofungin Brompheniramine Maleate Calcium Gluconate Cefaclor Buclizine Calcium Glycerophosphate Cefadroxil Budesonide Calcium Glycinate Cefazolin Bufexamac Calcium Hydroxide Cefdinir Buflomedil HCl Calcium Iodate Cefditoren Pivoxil Bumetanide Calcium L Methyl Folate Cefepime Bupivacaine Calcium Lactate Cefixime Buprenorphine Calcium Lactate Gluconate Cefoperazone Sodium Bupropion Calcium Lactobionate Cefotaxime Sodium Buserelin Acetate Calcium Levulinate Cefotetan Disodium Buspirone HCl Calcium Lysinate Cefoxitin Sodium Busulfan Calcium Maleate Cefpodoxime Proxetil Butabarbital Calcium Orotate Cefprozil Butamirate Citrate Calcium Peroxide Ceftazidime Butoconazole Nitrate Calcium Pidolate Ceftibuten Butorphanol Tartrate Calcium Propionate Ceftriaxone Cabazitaxel Calcium Pyruvate Cefuroxime Cabergoline Calcium Saccharate Celecoxib API List 2/9 Luna Investments Luna Investments - API List Product Name Celiprolol HCl Cisplatin Cyclosporine Cephalexin Citalopram Cyproheptadine HCl Cephapirin Citicoline Cyproterone Acetate Ceritinib Citicoline Sodium Dabigatran Cetirizine Clarithromycin Daclatasvir Cetrimide Clenbuterol HCl Dalfampridine Cetrorelix Clidinium Bromide Dalteparin Sodium Cetyl Dimethyl Ethyl Ammonium Clindamycin Dantrolene Sodium Bromide Cetyl Pyridinium Chloride Clobazam Dapagliflozine Cetyl Trimethyl Ammonium Bromide Clobenzorex HCl Dapoxetine HCL Chenodeoxycholic Acid Clobetasol Propionate Daptomycin Chlophedianol Hydrochloride Clobetasone Butyrate Darifenacin HBr Chlorcyclizine HCl Clocortolone Pivalate Darunavir Chlorhexidine Clodronic Acid Disodium Salt Dasatinib Chlormadinone Acetate Clofarabine Dasatinib Monohydrate Chlorobutanol Clomipramine HCl Daunorubicin HCl chloromethyl pivalate Clonazepam Decitabine Chloropyramine Hydrochloride Clonidine Deferasirox Chloroquine Clopidogrel Deferiprone Chlorphenaramine Maleate Cloprostenol Sodium Deferoxamine Mesylate Chlorthalidone Cloricromen HCl Deferoxamine Mesylate Sterile Cholecalciferol Closantel Base Deflazacort Cholesterol Clotrimazole Delmadinone Acetate Cholic Acid Cloxacillin Delta Tocotrienol Choline Bitartrate Clozapine Deoxycholic Acid Choline Chloride Cod Liver Oil Dequalinium Chloride Choline Dihydrogen Citrate Colchicine Dermantan Sulfate Choline Fenofibrate Colesevelam Desflurane Choline L Bitartrate Colistimethate Sodium Desloratadine Choline Orotate (Monohydrate) colistin sulphate Desmopressin Acetate Choline Salicylate Copper Bisglycinate Desonide Choline Theophyllinate Copper Citrate Desoximetasone Chondroitin Sulphate Copper Disodium Edetate Desoxycortone Pivalate Chymotrypsin Copper Gluconate Desvenlafaxine Ciclesonide Copper Glycinate Dexamethasone Cicletanine HCl Copper Lysinate Dexemdetomidine HCl Ciclomilast Copper Orotate Dexlansoprazole Ciclopirox Copper Pyrophosphate Dexmethylphenidate Cilastatin Sodium Cromolyn Dexrazoxane Cilazapril Curcumin Powder Dextroamphetamine Saccharate Cilostazole Cyanocobalamine Dextroamphetamine Sulfate Cimetropium Bromide Cyclidrol Dextromethorphan HBr Cinacalcet Cyclizine Dextrose Monohydrate Cinnarizine Cyclobenzaprine HCl Diacerein Ciprofibrate Cyclofenil Diazepam Ciprofloxacin Cyclophosphamide Dicaffeine Malate Cisatracurium Cycloserine Diclofenac Diethylammonium API List 3/9 Luna Investments Luna Investments - API List Product Name Diclofenac Potassium Dobutamine Epinastine HCl Diclofenac Sodium Docetaxel Epinephrine Dicloxacillin Dohyfral Epirubicin HCl dicyclohexylcarbodiimide Dolutegravir Eplerenone Dicyclomine HCl Domiphen Bromide Epoprostenol Sodium Didanosine Domperidone Eptifibatide Didecyl Dimethyl Ammonium Bromide Donepezil HCl Ergocalciferol Didecyl Dimethyl Ammonium Chloride Doripenem Ergometrine Dienogest Dorzolamide HCL Ergonovine Maleate diethoxybenzeneacetic acid Dothiepin HCl Ergotamine Tartrate diethoxybenzeneacetonitrile Doxazosin Mesylate Erlotinib HCl diethoxybenzeneethanamine Doxepin HCl Ertapenem DiEthyl Amine (DEA) Doxofylline Erythromycin Di-Ethyl Amino Ethanol (DEAE) Doxorubicin HCL Erythropoietin (EPO) Diethyl Carbamazine Citrate Doxycicline Base Escin Diethylamine Salicylate Doxylamine Succinate Escitalopram Diethylpropion HCl D-Pseudoephedrine HCl Esculin Diflorasone D-Pseudoephedrine Sulfate Eslicarbazepine Acetate Dried Aluminum Hydroxide Gel Diflucortolone Valerate Esomeprazole Powder Difluprednate Drofenine Hydrochloride Esomeprazole Trihydrate Digitoxigenin Dronedarone Estradiol Digitoxin Drospirenone Eszopiclone Dihydroartemisinin Drotaverine hcl Etafedrine HCl Dihydroergocristine Mesylate Droxidopa Ethambutol HCl Dihydroergotamine Mesylate Duloxetine Ethamsylate Dihydroergotoxine Mesylate Dusogel Ethamsylate Dihydroergotoxinmonomethane Dutasteride Ethinyl Estradiol sulfonate (DCCK) Dihydrotachysterol 2/ DHT2 Dydrogesterone Ethyl Acetate Dihydroxicalciferol Econazole Etidronate Dihydroxyaluminum Sodium Carbonate Edoxaban Etodollac (DASC) Dihydroxypropyl theophylline Efavirenz Etofamide DiIodohydroxyquinoline Efinaconazole Etofenamate Diloxanide Furoate Eldecalcitol Etofibrate Diltiazem HCl Eletriptan HBr Etoposide Dimenhydrinate Eltrombopag Etoricoxib Dimethyl Formamide Elvitegravir Etravirin Dimethyl Fumarate Emetine HCl Etretinate dimethyl sulphate 98% Empagliflozin Everolimus Dinoprost Emtricitabine Exemestane Dinoprostone Enalapril Maleate Exenatide Diphenhydramine Enoxaparin Ezetimibe Diphenoxylate HCl Enrofloxacin Ezogabine DiPiperazine Sulphate Entacapone Famciclovir Dipyridamole Entecavir Famotidine Dipyrone Enzalutamide Febantel DiSodium Citrate Eosin Disodium Febuxostat Divalproex Sodium Ephedrine Felbamate API List 4/9 Luna Investments Luna Investments - API List Product Name Fenofibrate Flupirtine Halomethasone Monohydrate Fenofibric Acid Flurandrenolide Haloperidol Fenoterol HBr Flurbiprofen Haloperidol Decanoate Fenretinide Flutamide Halothane Fentanyl Fluticasone Heparin Calcium Ferric Ammonium Citrate fluvastatin Heparin Sodium Ferric Carboxymaltose Fluvoxamine Maleate
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • WO 2017/048702 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
    [Show full text]
  • A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs
    International Journal of Molecular Sciences Article A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs Milan Remko 1,*, Anna Remková 2 and Ria Broer 3 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovakia 2 Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Limbová 12, SK–833 03 Bratislava, Slovakia; [email protected] 3 Department of Theoretical Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +421-2-5011-7291 Academic Editor: Michael Henein Received: 18 February 2016; Accepted: 11 March 2016; Published: 19 March 2016 Abstract: Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissociation constants show that the active metabolites of prodrugs (ticlopidine, clopidogrel and prasugrel) and drugs elinogrel and cangrelor are completely ionized at pH 7.4. Both ticagrelor and its active metabolite are present at pH = 7.4 in neutral undissociated form. The thienopyridine prodrugs ticlopidine, clopidogrel and prasugrel are lipophilic and insoluble in water. Their lipophilicity is very high (about 2.5–3.5 logP values). The polar surface area, with regard to the structurally-heterogeneous character of these antiplatelet drugs, is from very large interval of values of 3–255 Å2.
    [Show full text]
  • Penile Injection Therapy | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Penile Injection Therapy This information will help you learn to inject medication into your penis. This is called penile injection therapy. Penile injections can help you achieve an erection if you have erectile dysfunction (ED). Read this resource carefully before starting injection therapy. If you do not follow the instructions in this resource, your doctor or APP may stop prescribing your penile injection medications and supplies. About Penile Injection Therapy The tissue that causes you to get an erection (erectile tissue) is a muscle. Going long periods of time without an erection is unhealthy for erectile tissue and may damage it. We believe having erections keeps erectile tissue healthy. A penile injection helps you have an erection. It works best if it’s given about 5 to 15 minutes before you want an erection. Penile Injection Therapy 1/19 Giving Yourself the Injection Your advanced practice provider (APP) will review the instructions below with you. Generally, the training for the injections takes 2 office visits. Please be aware that each visit may take up to 1 hour, so you should plan your schedule on the day of your appointment. Use this resource to help you the first few times you inject on your own. Do not take the following medications within 18 hours of injecting (before or after): Sildenafil (Viagra®) - 20 mg to 100 mg Vardenafil (Levitra®) - 10 mg to 20 mg Avanafil (Stendra®) - 50 mg to 200 mg If you take tadalafil (Cialis®) 10 mg or 20 mg, do not inject within 72 hours (3 days) of taking the medication.
    [Show full text]
  • Call for Methods
    CALL FOR METHODS Methods for Identification, Determination, or Screening Methods for PDE5 Inhibitors AOAC INTERNATIONAL invites method developers to submit methods for consideration and possible evaluation through the AOAC Official MethodsSM program. Prospective methods may be qualitative, identification methods, and/or screening methods for phosphodiesterase type 5 inhibitors (PDE5 inhibitors) in dietary ingredients and supplements. OBJECTIVE: The objective of this call for methods is to select and evaluate methods that can be used for routine surveillance of dietary ingredients. Acceptable methods must be reliable and reproducible when used by trained analysts in accredited laboratories. Interested method developers should provide a description of their proposed method and data characterizing the analytical performance of the proposed method. For the purpose of this Call-for-Methods, PDE5 inhibitors are defined as avanafil, lodenafil carbonate, mirodenafil, sildenafill, tadalafil, udenafil, or vardenafil; or any of their analogs. Any analytical technique that measures the analytes of interest and meets the method performance requirements specified in the SMPR will be considered. It is acceptable to have a different analytical method for each class of analytes. Applicable SMPRs: • View AOAC 2014.010 – Methods for the Identification of PDE5 Inhibitors • View AOAC SMPR 2014.011 – Methods for the Determination of PDE5 Inhibitors • View AOAC SMPR 2014.012 – Screening Methods for PDE5 Inhibitors Submit Your Method AOAC INTERNATIONAL METHOD SUBMISSION PROCESS: AOAC invites method authors to submit their methods with no fee required. Interested method authors or developers should provide a copy of their proposed method, as well as any available data characterizing the analytical performance and scientific validity of the method in AOAC format.
    [Show full text]
  • Health and Social Outcomes Associated with High-Risk Alcohol Use
    Manitoba Centre for Health Policy Health and Social Outcomes Associated with High-Risk Alcohol Use Summer 2018 Nathan C Nickel, MPH, PhD Jeff Valdivia, MNRM, CAPM Deepa Singal, PhD James Bolton, MD Christine Leong, PharmD Susan Burchill, BMus Leonard MacWilliam, MSc, MNRM Geoffrey Konrad, MD Randy Walld, BSc, BComm (Hons) Okechukwu Ekuma, MSc Greg Finlayson, PhD Leanne Rajotte, BComm (Hons) Heather Prior, MSc Josh Nepon, MD Michael Paille, BHSc This report is produced and published by the Manitoba Centre for Health Policy (MCHP). It is also available in PDF format on our website at: http://mchp-appserv.cpe.umanitoba.ca/deliverablesList.html Information concerning this report or any other report produced by MCHP can be obtained by contacting: Manitoba Centre for Health Policy Rady Faculty of Health Sciences Max Rady College of Medicine, University of Manitoba 4th Floor, Room 408 727 McDermot Avenue Winnipeg, Manitoba, Canada R3E 3P5 Email: [email protected] Phone: (204) 789-3819 Fax: (204) 789-3910 How to cite this report: Nathan C Nickel, James Bolton, Leonard MacWilliam, Okechukwu Ekuma, Heather Prior, Jeff Valdivia, Christine Leong, Geoffrey Konrad, Greg Finlayson, Josh Nepon, Deepa Singal, Susan Burchill, Randy Walld, Leanne Rajotte, Michael Paille. Health and Social Outcomes Associated with High-Risk Alcohol Use. Winnipeg, MB. Manitoba Centre for Health Policy, Summer 2018. Legal Deposit: Manitoba Legislative Library National Library of Canada ISBN 978-1-896489-90-2 ©Manitoba Health This report may be reproduced, in whole or in part, provided the source is cited. 1st printing (Summer 2018) This report was prepared at the request of Manitoba Health, Seniors and Active Living (MHSAL), a department within the Government of Manitoba, as part of the contract between the University of Manitoba and MHSAL.
    [Show full text]
  • The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane
    cancers Article The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane 1, 1, 1 2 3 Ki-Hyun Bang y, Young-Guk Na y , Hyun Wook Huh , Sung-Joo Hwang , Min-Soo Kim , Minki Kim 1, Hong-Ki Lee 1,* and Cheong-Weon Cho 1,* 1 College of Pharmacy, Chungnam National University, Daejeon 34134, Korea; [email protected] (K.-H.B.); [email protected] (Y.-G.N.); [email protected] (H.W.H.); [email protected] (M.K.) 2 College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 162-1 Songdo-dong, Yeonsu-gu, Incheon 406-840, Korea; [email protected] 3 College of Pharmacy, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan 609-735, Korea; [email protected] * Correspondence: [email protected] (H.-K.L.); [email protected] (C.-W.C.); Tel.: +82-42-821-5934 (H.-K.L. & C.-W.C.); Fax: +82-42-823-6566 (H.-K.L. & C.-W.C.) These authors contributed equally. y Received: 2 May 2019; Accepted: 10 June 2019; Published: 11 June 2019 Abstract: Strategies for the development of anticancer drug delivery systems have undergone a dramatic transformation in the last few decades. Lipid-based drug delivery systems, such as a nanostructured lipid carrier (NLC), are one of the systems emerging to improve the outcomes of tumor treatments. However, NLC can act as an intruder and cause an immune response. To overcome this limitation, biomimicry technology was introduced to decorate the surface of the nanoparticles with various cell membrane proteins. Here, we designed paclitaxel (PT)-loaded nanostructured lipid carrier (PT-NLC) with platelet (PLT) membrane protein because PLT is involved with angiogenesis and interaction of circulating tumor cells.
    [Show full text]
  • Gastroesophageal Reflux Disease (GERD)
    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Can PDE Inhibition Improve Cognition? : Translational Insights
    Can PDE inhibition improve cognition? : Translational insights Citation for published version (APA): Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht University. https://doi.org/10.26481/dis.20130418or Document status and date: Published: 01/01/2013 DOI: 10.26481/dis.20130418or Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
    [Show full text]
  • Ticagrelor – out with the Old, in with the New?
    Ticagrelor – out with the old, in with the new? Ticagrelor (Brilinta) is a new oral antiplatelet medicine, which has been available, fully subsidised, Special Authority criteria for ticagrelor with Special Authority, since 1 July, 2013. Ticagrelor, The Special Authority criteria for ticagrelor are the same co-administered with low dose aspirin, is an for both an initial application for use in a patient with an acute coronary syndrome (valid for 12 months) and for alternative to clopidogrel for the prevention of a second application for a subsequent acute coronary atherothrombotic events in patients with acute syndrome. Applications are able to be made by any coronary syndromes. In most cases, ticagrelor will relevant practitioner. Both the initial approval and renewal be initiated in hospital and continued for 12 months are valid for 12 months. after discharge. Prerequisites: 1. Patient has recently* been diagnosed with an Ticagrelor (pronounced tie-kag-re-lore), co-administered with ST elevation or non-ST elevation acute coronary aspirin as dual antiplatelet treatment, is indicated for the syndrome AND prevention of atherothrombotic events in adult patients with 2. Fibrinolytic therapy has not been given in the last acute coronary syndromes, such as ST elevation myocardial 24 hours and is not planned infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI). It is anticipated that for the majority of patients, * “Recently” in the context of this Special Authority is acute coronary ticagrelor will be initiated in hospital and then continued in syndrome diagnosed within a few days or weeks rather than months. the community after discharge. Patients will qualify under the Special Authority criteria (for the subsidised prescription of ticagrelor) whether they are treated with medical management N.B.
    [Show full text]
  • Package Leaflet: Information for the User Norvir 100 Mg Film-Coated Tablets Ritonavir Read All of This Leaflet Carefully Before
    Package leaflet: Information for the user Norvir 100 mg film-coated tablets ritonavir Read all of this leaflet carefully before you start taking this medicine because it contains important information for you or your child. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Norvir is and what it is used for 2. What you need to know before you or your child takes Norvir 3. How to take Norvir 4. Possible side effects 5. How to store Norvir 6. Contents of the pack and other information 1. What Norvir is and what it is used for Norvir contains the active substance ritonavir. Norvir is a protease inhibitor used to control HIV infection. Norvir is used in combination with other anti-HIV medicines (antiretrovirals) to control your HIV infection. Your doctor will discuss with you the best combination of medicines for you. Norvir is used by children 2 years of age or older, adolescents and adults who are infected with HIV, the virus which causes AIDS. 2. What you need to know before you or your child takes Norvir Do not take Norvir if you are allergic to ritonavir or any of the other ingredients of Norvir (see section 6).
    [Show full text]